Drug Trial Radar · NCT04821622
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
599
Actual
Start
May 12, 2021
Primary completion
Feb 18, 2026
Study completion Aug 28, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Inc
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
Conditions
- Prostate Cancer
Interventions
talazoparib plus enzalutamideDrug
experimental arm
Placebo plus enzalutamideDrug
Active comparator arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- radiological Progression-Free SurvivalTime frame: randomization up to 3 years
Locations
312 sites in 27 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Institute of Urology, PLLC
Tucson, Arizona
Beverly Hills Cancer Center
Beverly Hills, California
Adventist Health Glendale
Glendale, California
VA Long Beach Healthcare System
Long Beach, California
Yale-New Haven Hospital
New Haven, Connecticut
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Washington Cancer Institute at MedStar Washington Hospital Center
Washington D.C., District of Columbia
AdventHealth Medical Group Hematology and Oncology
Orlando, Florida
Investigational Drug Services, Advent Health Orlando
Orlando, Florida
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Austell, Georgia
Wellstar Cobb Hospital
Austell, Georgia
Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica
Carrollton, Georgia
West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica
Carrollton, Georgia
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Cartersville, Georgia
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Douglasville, Georgia
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta, Georgia
Comprehensive Urologic Care, SC
Lake Barrington, Illinois
Mid-Illinois Hematology & Oncology Associates, Ltd
Normal, Illinois
Henry Ford Health System
Detroit, Michigan
Henry Ford Medical Center - New Center One
Detroit, Michigan
Revive Research Institute, Inc.
Farmington Hills, Michigan
David C. Pratt Cancer Center
St Louis, Missouri
New Jersey Cancer Care, P.A.
Belleville, New Jersey
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York
Providence Cancer Institute Franz Clinic
Portland, Oregon
Providence Portland Medical Center
Portland, Oregon
Keystone Urology Specialists
Lancaster, Pennsylvania
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina
Bristol Regional Medical Center
Bristol, Tennessee
Ballad Health Cancer Care - Kingsport
Kingsport, Tennessee
Holston Valley Hospital and Medical Center
Kingsport, Tennessee
Indian Path Community Hospital
Kingsport, Tennessee
Kelsey Research Foundation
Houston, Texas
Oncology Consultants, P.A.
Houston, Texas
Kelsey-Seybold Clinic
Houston, Texas
oncology Consultants, P.A.
Houston, Texas
Kelsey-Seybold Clinic
Houston, Texas
Houston Metro Urology
Houston, Texas
Showing 40 of 312 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.